Pharmaceutical producer Adcock Ingram has reported a 24% rise in headline earnings per share (Heps) to 502 cents for the 12 months ended June 2022, boosted by an improved demand for its over-the-counter (OTC) and shopper healthcare merchandise.
The JSE-listed group which owns the Panado, Allergex, Citro-Soda, Corenza C and Bioplus manufacturers noticed 11.9% progress in income through the interval to R8.7 billion, whereas its gross margins improved to 35.1% from 34.5% within the earlier interval.
Profit progress through the interval was supported by value will increase in step with inflation for its OTC and shopper enterprise.
However, the value deflation it skilled within the Renal phase in addition to within the ARV phase of its prescription enterprise dampened these positive aspects. This noticed the group reporting an total value realisation of simply 1.5%.
Headline earnings elevated by 21% to R812 million, whereas buying and selling profit for the interval went up 21.6% to R1.1 billion, up from R915 million within the earlier interval.
“The group achieved healthy growth in turnover, with our flagship brand, Panado, reaching a new milestone, with annual sales in excess of R500 million. With some benefit from the exchange rate, we have seen an exceptional increase in trading profit and excellent cash generation,” CEO Andy Hall says in a press release on Thursday.
However larger promoting and distribution bills associated to its improved turnover, in addition to elevated spend on advertising, drove the group’s working bills up by an additional 10% through the interval.
Adcock Ingram declared a last dividend of 105 cents per share, 25% larger than what was declared within the earlier 12 months.
Read: Aspen to halt Covid vaccine output as J&J orders dry up
Segmented evaluate
The group shopper enterprise – which competes within the healthcare, private care and residential care market – reported a 23.3% enhance in turnover to R1.56 billion. This phase’s progress was largely boosted by the inclusion of delicate skincare model Epi-max (which was beforehand counted within the prescription enterprise) within the shopper phase, in addition to its acquisition of varied manufacturers from Peppina in December 2021.
“On a like-for-like basis, excluding Epi-max, sales improved 14.3%, with key brands posting healthy growth, most notably Panado, which reached a landmark annual sales value in excess of R500 million, as well as Compral and ProbiFlora.”
The OTC phase of the enterprise noticed a turnover enchancment of 18.7% to R2.06 billion. This, the group says, was supported by the relief of Covid-19 associated restrictions, which noticed an uptick in demand for cough and chilly merchandise.
“Citro-Soda, Allergex, Corenza-C, Alcophyllex and Dilinct all posted double digit ex-factory growth.”
“Gross profit improved 15.2%, but the gross margin is lower than the prior year, mainly due to the rate of acceleration in the cost of raw materials, utilities and wages.”
In comparability with the efficiency of the OTC and shopper segments, the group’s Prescription and Hospital segments reported comparatively modest progress. The prescription and hospital segments reported a 6.8% and 5.9% rise in turnover for the interval to R3.2 billion and R1.88 billion respectively.
“This set of results is proof of our people’s ability to adapt to changing market conditions and is underpinned by a huge sales, marketing, and operational effort from all our employees during the year. Adcock Ingram remains confident in the resilience of its affordable and balanced portfolio of healthcare products,” Hall says.
“Given the ongoing weakness in the local economy, high fuel prices and the significant deterioration of the rand, much of our focus for 2023 will be on management of margins.” Hall provides.
Listen: Covid-19 impacts on Adcock Ingram’s year-end outcomes
